Effect of cyclooxygenase inhibitors etoricoxib and diclofenac sodium as well as their combinations with mexidol on behavior in rats
Abstract
The effect of non-steroidal anti-inflammatory drugs (NSAIDs), selective cyclooxygenase (COX)-2 inhibitor etoricoxib and non-selective COX inhibitor diclofenac sodium, on the behavior of rats was evaluated with a single oral administration at doses of 1 and 10 mg/kg individually and in combination with 2-ethyl-6-methyl-3-hydroxypyridine succinate (mexidol). Both COX inhibitors at a dose of 10 mg/kg decrease locomotor activity in the open field test, and the selective COX-2 inhibitor at a dose of 10 mg/kg also increases the duration of immobility of animals in the tail suspension test. The use of etoricoxib and diclofenac sodium at a low dose (1 mg/kg) with mexidol at a dose of 25 mg/kg, in which the latter enhances the antiinflammatory effect of the COX inhibitors, does not lead to behavioral deviations similar to those associated with the NSAIDs at a dose of 10 mg/kg. Moreover, combinations of COX inhibitors (1 mg/kg) and mexidol (25 mg/kg) increase the locomotor activity of rats. This justifies further research of the effect of antioxidants on the severity of the main and side effects of NSAIDs, especially when administered as a course.
About the Authors
E. A. Ivanova
Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
8, Baltiyskaya str., Moscow, 125315
A. I. Matyushkin
Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
8, Baltiyskaya str., Moscow, 125315
A. G. Vasilchuk
Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
8, Baltiyskaya str., Moscow, 125315
T. A. Voronina
Zakusov Institute of Pharmacology
Russian Federation
Russian Federation
8, Baltiyskaya str., Moscow, 125315
References
1. Murray C.J.L., Afshin A., Alam T., et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 // Global Health Metrics. 2018. Vol. 392. N 10159. P. 1789–1858.
2. Michopoulos V., Powers A., Gillespie C.F., Ressler K.J., Jovanovic T. Inflammation in fear- and anxietybased disorders: PTSD, GAD, and Beyond // Neuropsychopharmacol. 2017. Vol. 42. N 1. P. 254–270.
3. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs // New Engl. J. Med. 2005. Vol. 353. N 16. P. 1711–1723.
4. Bierhaus A., Wolf J., Andrassy M., et al. A mechanism converting psychosocial stress into mononuclear cell activation // Proc. Natl. Acad. Sci. U.S.A. 2003. Vol. 100. N 4. Р. 1920–1925.
5. Merkulov V.M., Merkulova T.I., Bondar N.P. Mechanisms of brain glucocorticoid resistance in stressinduced psychopathologies // Biochemistry. 2017. Vol. 82. N 3. P. 351–365.
6. Raison C.L., Lowry C.A., Rook G.A. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression // Arch. Gen. Psychiat. 2010. Vol. 67. N 12. P. 1211–1224.
7. Pace T.W., Mletzko T.C., Alagbe O., Musselman D.L., Nemeroff C.B., Miller A.H., Heim C.M. Increased stressinduced inflammatory responses in male patients with major depression and increased early life stress // Am. J. Psychiat. 2006. Vol. 163. N 9. P. 1630–1633.
8. Portanova J.P., Zhang Y., Anderson G.D., Hauser S.D., Masferrer J.L., Seibert K., Gregory S.A., Isakson P.C. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin-6 production in vivo // J. Exp. Med. 1996. Vol. 184. N 3. P. 883–891.
9. Nishino S., Ueno R., Ohishi K., Sakai T., Hayaishi O. Salivary prostaglandin concentrations: possible state indicators for major depression // Am. J. Psychiat. 1989. Vol. 146. N 3. P. 365–368.
10. Ohishi K., Ueno R., Nishino S., Sakai T., Hayaishi O. Increased level of salivary prostaglandins in patients with major depression // Biol. Psychiat. 1988. Vol. 23. N 4. P. 326–334.
11. Wang J., Dunn A.J. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism // Neurochem. Int. 1998. Vol. 33. N 2. P. 143–154.
12. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., Mohebbi-Rasa S., Raznahan M., Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: A double blind and placebo controlled trial // Depress. Anxiety. 2009. Vol. 26. N 7. P. 607–611.
13. Müller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Müller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Möller H-J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: Results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine // Mol. Psychiatr. 2006. Vol. 11. N 7. P. 680–684.
14. Rapoport S.I. Brain arachidonic and docosahexaenoic acid cascades are selectively altered by drugs, diet and disease // Prostag. Leukotr. Ess. 2008. Vol. 79. N 3–5. P. 153–156.
15. Hu K., Sjölander A., Lu D., Walker A.K., Sloan E.K., Fall K., Valdimarsdóttir U., Hall P., Smedby K.E., Fang F. Aspirin and other non-steroidal anti-inflammatory drugs and depression, anxiety, and stress-related disorders following a cancer diagnosis: a nationwide register-based cohort study // BMC Med. 2020. Vol. 18. N 1: 238.
16. Voronina T.A., Seredenin S.B. Analysis of the mechanism of psychotropic action of 3-hydroxypyridine derivative // Ann. I. Super. Sanita. 1988. Vol. 24. N 3. P. 461–466.
17. Воронина Т.А. Мексидол: основные нейропсихотропные эффекты и механизм действия // Фарматека. 2009. Т. 180. № 6. С. 28–31.
18. Ivanova E.A., Matyushkin A.I., Vasilchuk A.G., Voronina T.A. Ability of mexidol to enhance antiexudative effect of diclofenac sodium and etoricoxib in rats and mice with carrageenan-induced edema // Moscow Univ. Biol. Sci. Bull. 2021. Vol. 76. N 2. P. 46–51.
19. Воронина Т.А., Середенин С.Б., Яркова М.А., Воронин М.В. Методические рекомендации по доклиническому изучению транквилизирующего (анксиолитического) действия лекарственных средств // Руководство по проведению доклинических исследованию лекарственных средств / Под ред. А.Н. Миронова, Н.Д. Бунятян, А.Н. Васильева и др. М.: Изд-во ФГБУ НЦЭМСП Минздравсоцразвития России, 2012. С. 264–275.
20. Chermat R., Thierry B., Mico J.-A., Stéru L., Simon P. Adaptation of the tail suspension test to the rat // J. Pharmacol. 1986. Vol. 17. N 3. P. 348–350.
21. Шимширт А.А., Калинина Т.С., Воронина Т.А. Изучение влияния диазепама на тревожные реакции у мышей, вызванные индометацином // Рос. биотер. журн. 2012. Т. 11. № 1. С. 45–46.
22. Guo J.Y., Li C.-Y., Ruan Y.-P., Sun M., Qi X.-L., Zhao B.-S., Luo F. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressivelike behavior via reducing cyclooxygenase-2 expression in rat brain // Eur. J. Pharmacol. 2009. Vol. 612. N 1–3. P. 54–60.
23. Kessing L.V., Rytgaard H.C., Gerds T.A., Berk M., Ekstrøm C.T., Andersen P.K. Newdrug candidates for depression – a nationwide population-based study // Acta Psychiat. Scand. 2019. Vol. 139. N 1. P. 68–77.
24. Wium-Andersen I.K., Wium-Andersen M.K., Jørgensen M.B., Osler M. Anti-inflammatory treatment and risk for depression after first-time stroke in a cohort of 147487 Danish patients // J Psychiatr. Neurosci. 2017. Vol. 42. N 5. P. 320–330.
25. Aid S., Langenbach R., Bosetti F. Neuroinflammatory response to lipopolysaccharide is exacerbated in mice genetically deficient in cyclooxygenase2 // J. Neuroinflamm. 2008. Vol. 5: 17.
Review
For citations:
Ivanova E.A., Matyushkin A.I., Vasilchuk A.G., Voronina T.A. Effect of cyclooxygenase inhibitors etoricoxib and diclofenac sodium as well as their combinations with mexidol on behavior in rats. Vestnik Moskovskogo universiteta. Seriya 16. Biologiya. 2021;76(3):148-154. (In Russ.)
Views:
496
Email this article 